Surgery Partners Inc (SGRY)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Surgery Partners Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 3 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 15.40 $ — 32% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
2 of 10 Weak growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 9.2% failed
- More than 10% revenue growth is expected for the coming year 5.3% failed
- Share count grows by less than 3% a year 11.4% failed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 12.2% failed
- Gross margin at 40% or higher and without meaningful erosion 23.1% failed
- Goodwill from acquisitions does not grow faster than revenue 63.0% passed
- Net debt below twice EBITDA 6.7 x EBITDA failed
- Operating cash flow covers the profits of the last three years 1,126 m passed
- Return on capital at 15% or higher, or up versus two years ago 5.1% failed
- Insiders hold at least 10% or are net buyers 1.8% failed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Analysts & Price Target
The price target sits 21.0% above the current price.
- Consensus
- Sell
- Analyst Ratings
- 12
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 0.46 | 0.30 – 0.69 | 3,408 | -1.2% | 10 |
| 12/31/2027 | 0.67 | 0.40 – 0.94 | 3,588 | 43.9% | 10 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- -0.03 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.86 | – | 864 | 17.50 | -12.60 | 111 | 89 |
| 2025: Q1 | -0.30 | – | 776 | 8.20 | -4.90 | 6 | -17 |
| 2025: Q2 | -0.02 | – | 826 | 8.40 | -0.30 | 81 | 58 |
| 2025: Q3 | -0.18 | – | 822 | 6.60 | -2.80 | 84 | 64 |
| 2025: Q4 | -0.12 | – | 885 | 2.40 | -1.70 | 103 | 91 |
| 2026: Q1 | -0.28 | – | 811 | 4.50 | -4.40 | 12 | -4 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 1,145 | 196 | 9 | 0.20 | 125 | 10 | 2,305 |
| 2017 | 1,341 | 158 | -53 | -1.08 | 121 | 655 | 4,623 |
| 2018 | 1,771 | 78 | -206 | -4.28 | 145 | 405 | 4,676 |
| 2019 | 1,831 | 236 | -75 | -1.55 | 130 | 692 | 5,019 |
| 2020 | 1,860 | 183 | -116 | -2.38 | 247 | 550 | 5,413 |
| 2021 | 2,225 | 302 | -71 | -0.98 | 87 | 1,089 | 6,118 |
| 2022 | 2,539 | 345 | -55 | -0.59 | 159 | 1,998 | 6,682 |
| 2023 | 2,743 | 328 | -12 | -0.09 | 294 | 1,987 | 6,877 |
| 2024 | 3,114 | 349 | -168 | -1.33 | 300 | 1,790 | 7,890 |
| 2025 | 3,309 | 390 | -78 | -0.61 | 274 | 1,713 | 8,242 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Surgery Partners, Inc. besitzt und betreibt zusammen mit seinen Tochtergesellschaften ein Netzwerk chirurgischer Einrichtungen und begleitender Dienstleistungen in den USA.
| Employees | 16,000 |
|---|---|
| Headquarters | Brentwood, TN |
| Address | 340 Seven Springs Way, 37027 Brentwood, United States |
| Phone | 615 234 5900 |
| Website | surgerypartners.com |
| IPO Date | 1. Oct 2015 |
| ISIN | US86881A1007 |
Management
| Name | Title | Birth Year |
|---|---|---|
| J. Eric Evans | CEO & Director | 1977 |
| David T. Doherty CPA | Executive VP & CFO | 1972 |
| Jennifer B. Baldock J.D. | Executive VP and Chief Administrative & Development Officer | 1971 |
| Marissa A. Brittenham | Executive VP & Chief Strategy Officer | 1985 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 18. Jun 2026 | Hendrix Blair E | Director | Other | 34,364 | 14.55 | 499,996 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.